SCHEMBL4775150

SCHEMBL4775150

CN(C)CC(=O)N(CCS(=O)(=O)Nc1ccc(C(=O)NCc2ccc(C(F)(F)F)nc2)cc1)Cc1cccc(Cl)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.39
DGAT2 Q96PD7 1/20 0.39
EPHX2 P34913 3/20 0.38
NR1H4 Q96RI1 2/20 0.38
NAMPT P43490 5/20 0.38
SCN3A Q9NY46 2/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LSS P48449 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775184 0.91 MAPT (0.41) MAPTGAADGAT2EPHX2NR1H4
SCHEMBL4773601 0.86 MAPT (0.39) MAPTGAADGAT2EPHX2NR1H4
SCHEMBL4767854 0.85 MAPT (0.46) MAPTDGAT2EPHX2NR1H4NAMPT
SCHEMBL4772464 0.81 GAA (0.48) MAPTGAADGAT2NAMPTLSS
SCHEMBL4768230 0.81 NAMPT (0.46) GAADGAT2NAMPTSCN3ALSS
SCHEMBL4771179 0.80 GAA (0.47) MAPTGAADGAT2NAMPTLSS
SCHEMBL4775154 0.80 GAA (0.45) MAPTGAADGAT2NAMPTSCN3A
SCHEMBL4768151 0.80 MAPT (0.49) MAPTGAADGAT2EPHX2NAMPT
SCHEMBL4774981 0.80 MAPT (0.46) MAPTDGAT2EPHX2NR1H4NAMPT
SCHEMBL4767863 0.79 GAA (0.61) MAPTGAADGAT2NAMPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885GAA 466/4885DGAT2 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.